boehringer glp 1 links GLP-1 agonist to scarring improvements in MASH Companies are racing to improve

Production starts after finalizing the legal agreement & approvals

The Phase I paradox: intermediate metabolites are often more toxic than the parent compounds

Range of motion may increase, pain levels during activities often decrease, and overall function begins improving measurably

Some people taking glucagon-like peptide 1 (GLP-1) receptor agonists a type of medication used to support weight loss and manage type 2 diabetes experience gastrointestinal (GI) side effects, including diarrhea

GLP-1 Statistics 2026: What the Head-to-Head Data Shows A balanced look at the largest real-world comparisons between metabolic and bariatric surgery and GLP-1 medications weight loss outcomes, cost, durability, and why the two are increasingly discussed as options along the same care pathway rather than competitors